Xeris Biopharma Holdings (XERS) Revenue (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Revenue for 7 consecutive years, with $92.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 28.74% year-over-year to $92.1 million; the trailing twelve-month figure through Jun 2026 stood at $335.4 million (up 36.33% YoY), and the FY2025 full-year result was $291.8 million, up 43.72% from the prior year.
• Revenue grew to $92.1 million in Q2 2026 per XERS's latest filing, from $83.1 million in the prior quarter.
• Across five years, Revenue topped out at $92.1 million in Q2 2026 and bottomed at $22.1 million in Q1 2022.
• Historically, Revenue has averaged $52.5 million across 5 years, with a median of $48.2 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Revenue surged 184.15% in 2022, then increased 12.31% in 2024.
• Over 5 years, Revenue stood at $33.1 million in 2022, then surged by 33.93% to $44.4 million in 2023, then soared by 35.39% to $60.1 million in 2024, then jumped by 42.78% to $85.8 million in 2025, then rose by 7.33% to $92.1 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $92.1 million, $83.1 million, and $85.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.